Welcome to: Rimonabant Information Source (rimonabant tablets)

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 |
Effective weight loss with Rimonabant
- buy rimonabant buy acomplia
- rimonabant tablets
- rimonabant short term
- loose weight, rimonabant
- rimonabant fda approved
- rimonabant generic manufacturer
- rimonabant sanofi
Rimonabant Pricelist
Please wait while we load the price list
RimonabantReport.com). First-year results from the RIO-Europe study fueled excitement over the potential of this new type of obesity drug when they were presented last August at the European Society of Cardiology (ESC) 2004 Congress. The enthusiasm over this drug then surged in November, when two-year findings from the RIO-North America trial showed that Acomplia helped obese and overweight people lose significantly more weight -- and keep the weight off -- than a placebo. With Sanofi reported still planning to file for initial regulatory approvals to sell Acomplia in the second quarter of this year, obesity experts are eagerly awaiting two-year results from the RIO-Europe trial for two reasons: To see if the RIO-Europe trial continues to support the highly encouraging two-year findings from the RIO-North America trial.
Obesity is a widespread dietary disorder which has entrapped the young and the aged in its ambit. Obesity is not only a danger in itself but tags along many other health risks such as high cholesterol, high blood pressure. Henceforth, it is very essential to tackle such a health situation promptly. Acomplia diet pill by facilitating weight loss can help you in this endeavor easily. Acomplia with Rimonabant as its active ingredient is an effectual weight loss drug. It is developed by a French pharmaceutical firm known as Sanofi-Aventis. It has created a rage among millions of obese since its launch due to its effective weight loss results. Acomplia diet tablet is available in the UK, Germany amidst other countries. It still awaits its launch in the huge US weight loss market due to the withheld FDA approval.
